The -13.88% Decline of Entrada Therapeutics Inc’s (TRDA) Stock in the Past Quarter

In the past week, TRDA stock has gone up by 2.99%, with a monthly decline of -12.26% and a quarterly plunge of -17.84%. The volatility ratio for the week is 5.39%, and the volatility levels for the last 30 days are 5.07% for Entrada Therapeutics Inc The simple moving average for the past 20 days is -2.53% for TRDA’s stock, with a -44.23% simple moving average for the past 200 days.

Is It Worth Investing in Entrada Therapeutics Inc (NASDAQ: TRDA) Right Now?

The price-to-earnings ratio for Entrada Therapeutics Inc (NASDAQ: TRDA) is above average at 8.94x, Company’s 36-month beta value is -0.11.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy”, 2 as “overweight”, 0 as “hold”, and 0 as “sell”.

The public float for TRDA is 22.21M, and currently, short sellers hold a 4.96% ratio of that floaft. The average trading volume of TRDA on July 04, 2025 was 153.46K shares.

TRDA stock’s latest price update

Entrada Therapeutics Inc (NASDAQ: TRDA)’s stock price has dropped by -0.55% in relation to previous closing price of $7.27. Nevertheless, the company has seen a gain of 2.99% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that BOSTON, June 03, 2025 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.

Analysts’ Opinion of TRDA

Many brokerage firms have already submitted their reports for TRDA stocks, with ROTH MKM repeating the rating for TRDA by listing it as a “Buy”. The predicted price for TRDA in the upcoming period, according to ROTH MKM is $29 based on the research report published on December 06, 2024 of the previous year 2024.

Oppenheimer, on the other hand, stated in their research note that they expect to see TRDA reach a price target of $22. The rating they have provided for TRDA stocks is “Outperform” according to the report published on January 05th, 2024.

TRDA Trading at -9.33% from the 50-Day Moving Average

After a stumble in the market that brought TRDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.82% of loss for the given period.

Volatility was left at 5.07%, however, over the last 30 days, the volatility rate increased by 5.39%, as shares sank -8.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.99% lower at present.

During the last 5 trading sessions, TRDA rose by +2.99%, which changed the moving average for the period of 200-days by -51.80% in comparison to the 20-day moving average, which settled at $7.42. In addition, Entrada Therapeutics Inc saw -49.51% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TRDA starting from PARMAR KUSH, who sold 75,000 shares at the price of $6.91 back on Jun 27 ’25. After this action, PARMAR KUSH now owns 1,113,092 shares of Entrada Therapeutics Inc, valued at $518,250 using the latest closing price.

PARMAR KUSH, the Director of Entrada Therapeutics Inc, sale 25,000 shares at $7.12 during a trade that took place back on Jul 01 ’25, which means that PARMAR KUSH is holding 1,100,248 shares at $178,065 based on the most recent closing price.

Stock Fundamentals for TRDA

Current profitability levels for the company are sitting at:

  • 0.02% for the present operating margin
  • 0.98% for the gross margin

The net margin for Entrada Therapeutics Inc stands at 0.14%. The total capital return value is set at 0.01%. Equity return is now at value 7.22%, with 4.97% for asset returns.

Based on Entrada Therapeutics Inc (TRDA), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.96.

Currently, EBITDA for the company is 47.01 million with net debt to EBITDA at -1.79. When we switch over and look at the enterprise to sales, we see a ratio of 1.53. The receivables turnover for the company is 84.26for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.88.

Conclusion

In a nutshell, Entrada Therapeutics Inc (TRDA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts

favicon-nh
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.